COVID-19 Vaccine Injury Compensation in Ireland: A Comprehensive Legal and Policy Analysis

Introduction: A Collective Act, An Individual Burden

The COVID-19 vaccination programme represents one of the most significant public health undertakings in the history of the Irish State. It was a collective act of social solidarity, undertaken to protect the vulnerable, preserve the healthcare system, and restore normality to society. The overwhelming scientific consensus confirms that the vaccines deployed were, and remain, remarkably safe and effective, saving countless lives by preventing severe illness, hospitalisation, and death.¹

However, this report addresses the profound paradox at the heart of this public health success. While vaccines are exceptionally safe, no medical intervention is entirely without risk.⁴ In the rare instances where individuals in Ireland suffered severe, debilitating, and life-altering health consequences following a COVID-19 vaccination, they and their families have been confronted with a stark reality: a legal and financial landscape devoid of a clear path to support or redress. Unlike many of its international peers, Ireland has failed to establish a state-backed, no-fault compensation scheme to assist this small but significantly impacted group.⁴

This policy vacuum creates a deep ethical inconsistency. As legal experts and official government reports have argued, the State, having actively encouraged mass vaccination for the common good, bears a strong moral responsibility to provide for those who, through no fault of their own, were harmed in this collective effort.⁸ This report provides a comprehensive analysis of the current situation in Ireland. It examines the fractured legal avenues available to claimants, clarifies the role of the State and its agreements with vaccine manufacturers, chronicles the stalled progress towards a promised compensation scheme, and places Ireland’s inaction in a critical international context. The aim is to deliver clarity to those affected and to outline the pressing need for policy reform.

Section 1: The Irish Compensation Landscape: A System in Limbo

The central challenge for anyone seeking compensation for a COVID-19 vaccine injury in Ireland is the absence of a dedicated, fit-for-purpose system. This leaves Ireland as a notable outlier among many developed nations, with a significant gap in its social safety net that the pandemic has brought into sharp focus.

1.1 The Concept of a No-Fault Vaccine Injury Compensation Programme (VICP)

A no-fault Vaccine Injury Compensation Programme, or VICP, is a specialised, state-administered system designed to provide financial redress to individuals who have suffered serious harm as a rare consequence of vaccination.⁴ The defining feature of these schemes is that they remove the need for a claimant to prove negligence or fault on the part of the vaccine manufacturer, the government, or the healthcare professional who administered the dose.¹¹

The primary purpose of a VICP is to offer a more accessible, faster, and less adversarial alternative to the traditional court system.⁴ Litigation in cases of alleged vaccine injury is notoriously complex, lengthy, and expensive, with the burden of proving a direct causal link between the vaccine and the injury presenting a formidable, often insurmountable, scientific and legal hurdle for an individual claimant.⁶ By operating on a “no-fault” basis, these schemes focus on establishing causation to a specific standard of proof, rather than proving a breach of duty. Before the COVID-19 pandemic, at least 25 jurisdictions worldwide, including 16 in Europe, had already established such programmes, recognising them as a vital component of a comprehensive public immunisation strategy.⁴

1.2 Ireland’s Position: A Long-Standing Policy Vacuum

Ireland does not have a Vaccine Injury Compensation Programme.⁴ This is not a recent oversight in response to the COVID-19 pandemic but a well-documented policy failure stretching back decades. The issue of establishing a vaccine damage compensation scheme has been under official consideration since at least 2001, when the Oireachtas Joint Committee on Health and Children first recommended its creation.⁴ This was followed by a 2009 report from a dedicated Steering Group, which again recommended the establishment of a VICP.¹² There is even historical precedent for such a system; a limited, ex-gratia payment scheme was operated in the late 1970s and early 1980s for a small number of children believed to have been harmed by the whooping cough vaccine.¹⁰

The failure to act on these repeated recommendations over two decades meant that when the COVID-19 crisis arrived, Ireland was legally unprepared for the consequences of a mass vaccination campaign.¹³ The unique circumstances of the pandemic—particularly the granting of legal indemnity to vaccine manufacturers—transformed this long-standing policy gap from a theoretical problem into an acute crisis for the small number of individuals who suffered serious adverse events.⁴

1.3 The Ethical and Pragmatic Case for a Scheme

The arguments in favour of establishing a VICP in Ireland are both ethical and pragmatic, and have been forcefully articulated by legal experts and in official government-commissioned reports.

• The Moral Argument: The State, through the HSE, urged the entire population to get vaccinated, framing it as a civic duty to protect oneself, the community, and the health service. People were asked to “roll up the sleeve and take one for the green jersey”.⁹ In this context, there is a powerful ethical argument that the State has a reciprocal obligation to accept responsibility for and provide support to the very few who were severely harmed as a result of answering that call.²
• Pragmatic Arguments: Beyond the ethical imperative, there are several practical reasons to establish a scheme:

• Maintaining Public Confidence: A transparent and fair compensation scheme demonstrates that the State stands behind its public health recommendations. This can bolster trust and reduce vaccine hesitancy in current and future immunisation campaigns by reassuring the public that they will not be abandoned in the rare event of an injury.²
• Ensuring Vaccine Supply: Offering manufacturers protection from extensive and costly litigation was a key part of the EU’s vaccine procurement strategy. State-run compensation schemes are a core component of this liability framework, helping to ensure a stable and willing supply of vaccines.⁴
• Reducing Litigation Costs: A well-designed administrative scheme provides a more efficient and less costly mechanism for resolving claims than protracted and complex court battles against the State, which are ultimately funded by the taxpayer.⁷

1.4 Clarifying Misinformation: Does Ireland have a Vaccine Damage Payment Scheme (VDPS)?

It is crucial to correct a significant piece of misinformation that has appeared in some online resources. One source incorrectly claims that Ireland has a “Vaccine Damage Payment Scheme (VDPS)” administered by the Department of Health.¹⁵ This is unequivocally false. This error is likely a result of confusion with the United Kingdom’s scheme, which is officially named the Vaccine Damage Payment Scheme (VDPS).¹⁶ Multiple authoritative sources, including Oireachtas research papers, government statements, and legal analyses, confirm that no such scheme, by any name, currently exists in Ireland.⁴ For individuals seeking information on making a claim, this is a critical clarification.

Section 2: Avenues for Redress: A Fractured Legal Framework

In the absence of a no-fault compensation scheme, individuals in Ireland who believe they have been injured by a COVID-19 vaccine are left with only the traditional legal system. However, the viability of a claim depends entirely on the nature of the injury, creating a fractured and unequal two-tier system of access to justice.

2.1 Pathway 1: Medical Negligence for Errors in Administration

The first, more viable pathway is a claim based on medical negligence. This route is not for injuries caused by the vaccine’s inherent properties, but for harm resulting from an error in how the vaccine was administered by a healthcare professional.⁸

The most common and well-documented example of such an injury is Shoulder Injury Related to Vaccine Administration (SIRVA). This is a preventable injury that occurs when a vaccine is injected too high up on the arm, into the sensitive shoulder capsule and joint structures, rather than into the thick deltoid muscle.¹⁷ Symptoms of SIRVA can be severe and debilitating, including intense and prolonged shoulder pain, significantly limited range of motion, rotator cuff tears, subacromial bursitis, and adhesive capsulitis, more commonly known as “frozen shoulder”.¹⁷

The legal basis for such a claim is the standard tort of medical negligence. To succeed, a claimant must prove three things on the balance of probabilities:

1. A duty of care was owed by the vaccinator to the patient (this is automatic in a healthcare context).
2. There was a breach of that duty, meaning the vaccinator’s technique fell below the accepted standard of care for administering an intramuscular injection.¹⁵
3. This breach of duty was the direct cause of the resulting shoulder injury.¹⁷

While this is a recognised legal path, it is not without challenges. A claim may fail if there is insufficient evidence to prove the injection technique was improper, if medical experts cannot definitively link the injury to the vaccination procedure, or if a pre-existing shoulder condition is determined to be the primary cause of the symptoms.¹⁷ Furthermore, the strict two-year statute of limitations for personal injury claims is a critical and unforgiving deadline that claimants must meet.⁸

2.2 Pathway 2: Inherent Side Effects & The Litigation Hurdle

The second pathway is for those who suffer a serious adverse reaction from a correctly administered vaccine. This category includes rare but recognised side effects such as myocarditis (inflammation of the heart muscle), pericarditis (inflammation of the lining around the heart), Guillain-Barré syndrome, blood disorders, or the onset of autoimmune conditions like Graves’ disease.⁵

For these individuals, the situation is far more perilous. As one legal firm bluntly states, “as things currently stand, the second category does not have any entitlement to compensation” through any straightforward mechanism.⁸ Their only option is to initiate a complex and costly legal action, likely based on product liability law, arguing that the vaccine was defective.⁶ This path is fraught with immense, and likely insurmountable, hurdles for an individual claimant.

The primary obstacle is proving causation to a legal standard. The claimant bears the enormous evidentiary burden of demonstrating, with robust scientific and medical expert testimony, that the vaccine itself was the direct cause of their specific injury, and not a coincidental event or an underlying health issue.⁶ This is exceptionally difficult and expensive to do. Furthermore, claimants face the “state of the art” or “warned side-effects” defence, where manufacturers and the State can argue that while certain rare side effects were known risks, they were disclosed, and the overall benefit of vaccination during a pandemic far outweighed these minimal risks.⁶

The State’s indemnity of the manufacturers (discussed in Section 3) does not ease this burden. It simply means the State Claims Agency becomes the defendant, but it will still require the claimant to prove their case under the full, rigorous standards of the fault-based legal system—the very system a no-fault scheme is designed to bypass.¹⁸

2.3 The Critical Importance of Timely Legal Advice

Given this complex legal environment, the statute of limitations is a crucial factor. In Ireland, a personal injury claim must generally be initiated within two years of the date of injury or the date of knowledge of the injury. For many who received their primary COVID-19 vaccine doses in 2021, this critical deadline may have already passed or is rapidly approaching. Legal professionals have strongly advised individuals who have suffered serious and lasting complications to seek immediate legal counsel and consider issuing “precautionary proceedings”.⁸ This action serves to protect their potential right to a claim, preventing them from being “statute barred” while the broader policy and legal situation remains unresolved.

The following table clearly illustrates the two-tiered system of justice facing vaccine injury claimants in Ireland.

Parameter	Pathway 1: Negligent Administration (e.g., SIRVA)	Pathway 2: Inherent Side Effect (e.g., Myocarditis)
Legal Basis	Medical Negligence (Tort)	Product Liability / Litigation against the State
Core Allegation	Improper technique by healthcare professional.	The vaccine itself was defective or caused harm.
Burden of Proof	Prove the administration was below the accepted standard of care and that this breach caused the injury.	Prove a direct scientific and causal link between the vaccine and the injury, overcoming warnings of known rare side effects.
Primary Challenge	Gathering evidence of improper technique; ruling out pre-existing conditions.	Establishing scientific causation to a legal standard; the immense cost and complexity of litigation.
Likely Defendant	State Claims Agency (acting for the HSE/vaccinator).	State Claims Agency (acting for the manufacturer due to indemnity).
Viability	Challenging, but a recognised and viable legal path with precedent.	Extremely difficult, costly, and with a very low probability of success in the absence of a no-fault scheme.

Section 3: The State’s Role: Indemnity, Liability, and the State Claims Agency (SCA)

To fully understand the predicament of those seeking compensation, it is essential to examine the legal architecture constructed by the State during the pandemic. Through a series of EU-level agreements, the Irish State shielded vaccine manufacturers from liability and designated a single state body—the State Claims Agency—as the gatekeeper for all potential claims.

3.1 The Shield of Indemnity: How Liability Shifted to the State

In the global race to develop and procure COVID-19 vaccines, speed was of the essence. To facilitate this, the European Commission negotiated a series of Advanced Purchase Agreements (APAs) with pharmaceutical companies on behalf of all EU member states, including Ireland.¹⁸ Given the unprecedented speed of vaccine development and the potential for unknown risks, manufacturers demanded protection from future civil liability claims as a condition of these agreements.⁴

The result was the inclusion of powerful indemnity clauses in the APAs. By opting into these agreements, Ireland and other member states agreed to indemnify the manufacturers against the costs of any legal claims arising from vaccine-related injuries.¹⁴ This means that if a person were to successfully sue for damages caused by a vaccine, the financial responsibility to pay that compensation would fall not on the pharmaceutical company that made the product, but on the Irish State.¹⁴ Ireland, as a participant in the EU’s collective bargaining process, did not have the power to unilaterally recast these terms; the choice was effectively to accept the indemnity conditions or risk being left without access to the EU’s portfolio of vaccines.¹⁸

3.2 The State Claims Agency (SCA): The Designated Gatekeeper

Once the Irish government formally accepted these indemnity provisions, the operational responsibility for handling any subsequent personal injury claims was delegated to the State Claims Agency (SCA).¹⁸ The SCA is the statutory body responsible for managing all personal injury and property damage claims against the State and its authorities, including the Health Service Executive (HSE).¹⁸ To ensure comprehensive cover, the State also extended a state-backed indemnity to all GPs, nurses, pharmacists, and other healthcare professionals who participated in the vaccine rollout, meaning any negligence claim against them would also be managed and defended by the SCA.²¹

The process for handling these claims is managed through the SCA’s established litigation procedures:

• Incident Reporting: All clinically significant adverse events related to the COVID-19 vaccines are required to be reported on the National Incident Management System (NIMS).²² The SCA monitors this data to identify risks and inform the HSE, but this reporting does not initiate a claim.²²
• Claim Initiation and Investigation: A formal legal claim is typically initiated by a solicitor’s letter sent to the relevant state body, which is then forwarded to the SCA. The SCA’s Clinical Claims Unit takes control of the case, launching a full investigation that includes commissioning independent expert medical reports to assess liability.²⁴
• Adversarial Defence: Based on its investigation, the SCA determines its legal strategy. It is crucial to understand that the SCA’s mandate is to manage legal risk and costs for the State, not to administer a compensation fund. It is an adversarial body. If the SCA determines the State is not legally liable under the strict requirements of existing fault-based law, it will vigorously defend the claim in court.²⁵

This legal arrangement has created a difficult paradox. The State’s indemnity was a necessary step to secure the vaccines needed to end the pandemic. However, by shifting liability from the manufacturer to the State without simultaneously creating a simplified, no-fault pathway for redress, the system has inadvertently trapped claimants. They can no longer sue the company that made the product, and their only recourse is to sue the State, which in turn has tasked its expert litigation defence agency, the SCA, to handle the case. This places the injured citizen in a direct, adversarial conflict with the State, facing the same high legal and evidentiary hurdles that a no-fault scheme is expressly designed to eliminate.

Section 4: A Scheme Deferred: Government Promises and Policy Paralysis

The Irish government was warned of the need for a vaccine injury compensation scheme before the first COVID-19 vaccine was even administered. Yet, years later, those affected are still waiting, met with a consistent pattern of delay and what has been described as policy paralysis.

4.1 The Meenan Report: An Urgent Recommendation Ignored

In December 2020, the Expert Group to Review the Law of Torts and the Current Systems for the Management of Clinical Negligence Claims, chaired by Mr Justice Charles Meenan, published its report. Recognising the impending mass vaccination campaign, the report unequivocally recommended the introduction of an ex-gratia (no-fault) scheme for people who suffer injury from vaccination programmes “as a matter of urgency”.⁸ This provided the government with a clear, proactive, and expert-backed directive to establish a safety net before the inevitable rare cases of injury emerged.

4.2 A Pattern of Delay: “Work is Ongoing”

Despite the urgency highlighted by the Meenan Report, an analysis of Dáil Éireann records from 2021 through to mid-2024 reveals a consistent and unchanging government response to questions about the scheme’s progress. In parliamentary questions from deputies across the political spectrum, the Minister for Health, Stephen Donnelly, and the Department of Health have repeatedly issued near-identical statements.²⁶

The standard reply asserts that “work is ongoing to design a proposed model for a vaccine damage scheme,” that officials are “working through related policy matters,” and that the development “needs detailed consideration to ensure that it is appropriately designed” before being brought to Cabinet for approval.²⁰ This response has remained static for years, offering no tangible evidence of progress, no estimated timeline for completion, and no draft legislation.⁷ This has led to accusations that the government is failing to deliver and has created deep disappointment among those waiting for a resolution.⁷

4.3 The Distinction Without a Difference: General vs. COVID-19 Scheme

A key nuance in the government’s official position has been the repeated insistence that there are “no plans at present for the introduction in Ireland of a Covid-19 specific vaccine compensation scheme”.⁹ The stated policy is to create a

general scheme that would cover all of the State’s vaccination programmes, not just for COVID-19.

While this may seem like a reasonable long-term policy goal, it has provided little comfort to those injured during the largest vaccination campaign in the State’s history. For this specific cohort, the distinction is academic. The practical outcome is the same: there is no scheme available to them. This position has been labelled an “absolute scandal” by senior legal professionals who argue that it fails to address the immediate needs of those harmed by the COVID-19 vaccines.⁹ The consistent repetition of this talking point, combined with the years of inaction on the general scheme, suggests it may function as a political framing device to deflect from the urgent, pandemic-related issue at hand.

4.4 The Human Cost of Inaction

This policy inertia has a real human cost. Individuals suffering from severe and persistent symptoms following vaccination have been left in a “very vulnerable position”.⁷ Without a scheme, their only recourse is to consider the daunting prospect of litigation—a process that is costly, emotionally draining, uncertain, and can take many years to resolve. They face the burden of suing for compensation to cover their pain and suffering, ongoing medical expenses, and significant loss of earnings, a situation that a no-fault scheme is precisely intended to prevent.⁷ For those who believe they acted for the collective good, the feeling is one of being left with “no fall back compensation” from a State that has washed its hands of them.⁹

Section 5: International Benchmarks: A Comparative Analysis of Compensation Models

Ireland’s failure to establish a compensation scheme stands in stark contrast to the approaches taken by many of its international and European partners. An examination of these existing models reveals a range of viable options and highlights the features Ireland could adopt to address its policy deficit.

5.1 Case Study: The UK Vaccine Damage Payment Scheme (VDPS)

The United Kingdom has a long-established statutory scheme, the Vaccine Damage Payments Act 1979, which was promptly extended to cover COVID-19 vaccines in December 2020.²

• Compensation: The VDPS provides a one-off, tax-free payment of £120,000.¹⁶
• Eligibility Criteria: To qualify, a claimant must meet two stringent criteria. First, they must prove on the balance of probabilities that the vaccine caused their disability.³⁴ Second, and most contentiously, the resulting disability must be assessed as at least 60% “severely disabled”.³⁰
• Process and Legal Rights: The scheme is administered by the NHS Business Services Authority (NHSBSA).¹⁶ Crucially, the payment is considered an
  ex gratia award, not legal compensation. This means a successful claimant can still pursue a separate civil claim for further damages in court.¹⁶
• Critique: While the existence of the VDPS is a clear advantage over the Irish situation, the scheme is heavily criticised. The 60% disablement threshold is an extremely high bar that excludes many people with significant but less severe injuries. This is reflected in very low approval rates.³⁵ Furthermore, the fixed £120,000 payment, while substantial, may be insufficient to cover lifetime care and loss of earnings for someone with a profound disability.² Notably, the scheme’s rules explicitly exclude claims for Shoulder Injury Related to Vaccine Administration (SIRVA).³⁴

5.2 The European Mosaic: Diverse Approaches to Compensation

A comprehensive 2023 report from the University of Oxford confirms that around half of all countries in Europe have some form of no-fault compensation scheme covering COVID-19 vaccines, showcasing a wide variety of models.³⁷ This demonstrates that functional systems are not only possible but are the norm in many comparable nations.

• Funding and Administration: Most schemes are funded directly by central government (e.g., Denmark, Germany, France), while some Nordic countries use a public-private insurance model funded by levies (e.g., Finland, Sweden).³⁸
• Eligibility Thresholds: There is significant variation. The UK’s 60% disablement rule is a clear outlier. In contrast, Denmark’s scheme covers any injury, applying only a small deductible to the final payment. Finland requires an injury to cause incapacity for at least 30 consecutive days, while Italy’s scheme requires a permanent impairment.³⁸
• Compensation Structure: The differences are profound. Some, like the UK and Slovenia, offer fixed lump-sum payments. However, many of the most comprehensive schemes in Europe provide individualised compensation tailored to the claimant’s specific losses. Systems in Denmark, Finland, Sweden, France, and Germany can cover a wide range of damages, including medical expenses, ongoing care costs, loss of past and future earnings, pain and suffering, and survivor benefits for dependents.⁴
• Relationship with Litigation: The schemes’ interaction with the court system also differs. The UK allows parallel litigation. In France, accepting a scheme’s offer bars further court action. In Germany, the two routes are mutually exclusive. In Denmark and Finland, the schemes have subrogation rights, meaning they can pursue the manufacturer for reimbursement if they pay out a claim.³⁸

This variety of established, functional systems proves that there is no single “correct” model, but it also demonstrates that Ireland has a wealth of international experience from which to draw in designing a scheme that is fair, accessible, and fit for purpose.

Table 2: Comparative Overview of European Vaccine Injury Compensation Schemes

Feature	Ireland	United Kingdom	Denmark	Germany	France
Scheme Status	None Exists	Statutory (VDPA 1979)	Statutory (Patient Comp. Act)	Statutory (Infection Protection Act)	Statutory (Public Health Code)
Funding Source	N/A	Central Government	Central Government	Federal States	Health Insurance / State Grants
Eligibility Threshold	N/A	60% severe disablement	Any injury (small deductible applies)	Health/economic consequences beyond normal reaction	Any injury (no threshold)
Compensation	Via litigation only	Fixed £120,000 lump sum	Individualised (earnings, pain/suffering, etc.) with caps	Individualised (pensions, medical costs)	Individualised (full damages, non-binding guidelines)
Covers Loss of Earnings?	Yes (in a successful lawsuit)	No	Yes	Yes (as disability pension)	Yes
Right to Litigate	Only available option	Unaffected by scheme payment	Restricted (Subrogation)	Restricted (mutually exclusive)	Restricted (accepting offer bars litigation)

Source: Synthesised from ¹⁶

Section 6: The Data Story: Quantifying Side Effects and Claims

Understanding the scale of the vaccine injury issue requires examining the available data. However, this data comes with significant caveats and is marked by a critical information vacuum in Ireland regarding formal legal claims.

6.1 Reporting in Ireland: The HPRA Data

The Health Products Regulatory Authority (HPRA) is the state body responsible for monitoring the safety of all medicines, including vaccines. It operates a system for the voluntary reporting of suspected adverse reactions, or side effects.¹⁵

As of May 2025, the HPRA had received a total of 21,393 reports of suspected side effects associated with COVID-19 vaccines.³⁹ This figure is an update from May 2022, when 20,182 reports had been received from over 8 million administered doses.⁸

It is absolutely critical to interpret this data with caution. The HPRA explicitly states that these are reports of suspected side effects, not medically proven causal links.³⁹ A report simply reflects the suspicion of the person submitting it—be it a patient or a healthcare professional—that a medical event may be linked to the vaccine.⁴⁰ Many of these events may be coincidental, unrelated, or caused by an underlying illness.⁴⁰ The overwhelming majority of reported side effects are mild and short-lived, such as fever, fatigue, headache, and soreness at the injection site, which are normal immune responses.³

The HPRA system has, however, been crucial in monitoring for rare but serious safety signals. For example, it has tracked reports of myocarditis and pericarditis, receiving 135 such reports describing these inflammatory heart conditions.³

6.2 The Claims Black Hole: Lack of Official Irish Data

While the HPRA provides data on public concerns, there is a complete absence of official, public data from the State Claims Agency (SCA) on the number of formal legal claims for COVID-19 vaccine injuries it has received, managed, settled, or defended.⁴¹ The SCA periodically publishes data on general medication incidents, and its infographics show a notable spike in reports related to “viral vaccines” in 2021, coinciding with the COVID-19 rollout.⁴¹ However, it does not provide specific figures on the number of litigated claims, their outcomes, or any compensation paid.

A Dáil response from July 2022 stated that, up to that point, there had been “no costs associated with any such claims,” but this information is now significantly out of date and lacks the necessary detail to understand the current situation.¹⁹ This lack of transparency from the State’s litigation management body creates an information vacuum, making it impossible for the public, policymakers, or potential claimants to accurately gauge the scale of the legal challenges being mounted against the State.

6.3 International Claims Data: A Sobering Perspective

Data from international compensation schemes provides a sobering context and highlights how challenging it is to meet the evidentiary standards for compensation, even within established no-fault systems.

A 2024 comparative analysis of 14 jurisdictions revealed widely divergent approval rates for claims. Japan demonstrated a high approval rate of 74.29%, while the United States (3%) and the United Kingdom (2.64%) had some of the lowest rates. The median approval rate across all schemes was approximately 27%.³⁵

The UK data is particularly illustrative. As of late 2024, the VDPS had received 17,379 claims related to COVID-19 vaccines. Of these, only 194 claims had resulted in an award being paid.³⁶ This represents an approval rate of just over 1% of all claims filed, or around 2% of claims that had been fully processed. This extremely low success rate directly reflects the difficulty of meeting the scheme’s high 60% disablement threshold.

This international evidence demonstrates a crucial point: there is a vast difference between a suspected side effect reported by the public and a legally or administratively validated, compensable injury. The large number of HPRA reports indicates a significant level of public concern and post-vaccination health events. However, this is met by an opaque formal claims system in Ireland. Even if a scheme were established, the international data suggests that its specific design—particularly the criteria for causation and severity—would be the ultimate determinant of its accessibility and fairness.

Section 7: Conclusion and Recommendations

The mass COVID-19 vaccination programme was a necessary and successful public health intervention. However, the State’s failure to provide a safety net for the small number of individuals who suffered severe harm as a result has created a significant ethical and legal deficit.

7.1 Summary of Findings: A Precarious Position

This analysis confirms that individuals in Ireland with a suspected COVID-19 vaccine injury are in a uniquely precarious and unsupported position. The current legal framework constitutes a two-tier system of justice. Those with injuries from clear administrative errors, such as SIRVA, have a recognised, albeit challenging, path through medical negligence claims. In contrast, those with injuries arising from the inherent properties of a correctly administered vaccine face the near-impossible task of proving causation in a fault-based system, with their only recourse being complex, costly, and uncertain litigation against the State.

Through EU-level agreements, the Irish State accepted full financial liability from vaccine manufacturers. Yet, it has failed to create a corresponding accessible and non-adversarial system for its own citizens to seek redress. This has left the litigation-focused State Claims Agency as the sole, and highly adversarial, gatekeeper. Despite urgent recommendations dating back to before the pandemic and repeated promises since, the government has been caught in a state of policy paralysis, failing to establish a no-fault compensation scheme and leaving Ireland lagging behind many of its European peers. This inaction has imposed a heavy burden on those affected, forcing them to navigate their health challenges without adequate State support or a clear path to justice.

7.2 Recommendations for Affected Individuals

For any individual who believes they have suffered a serious injury as a result of a COVID-19 vaccine, the following steps are critical:

1. Seek Immediate Legal and Medical Advice: The absolute priority is to consult with a solicitor who specialises in medical negligence and personal injury law. They can provide an expert assessment of the viability of a potential claim. Simultaneously, it is vital that all health issues are thoroughly investigated, diagnosed, and documented by medical professionals to create a clear record.
2. Be Aware of the Statute of Limitations: The two-year time limit for bringing a personal injury claim in Ireland is a strict and unforgiving deadline. Anyone who has suffered a potential injury must act with urgency to consult a solicitor to ensure they are not “statute barred,” which would permanently extinguish their right to claim, regardless of the merits of their case.⁸ A solicitor may advise issuing precautionary proceedings to protect this right.
3. Manage Expectations: The legal path is long, arduous, and uncertain. As the international data shows, even in countries with established no-fault schemes, the success rates for claims can be very low.³⁵ Claimants must be prepared for a difficult process.
4. Engage with Patient Advocacy Groups: While Ireland does not have a dedicated vaccine injury support group akin to those in the UK ⁴³, general organisations like the Irish Patients’ Association or the Patient Advocacy Service may be able to offer guidance, support, and resources.⁴⁴

7.3 Recommendations for Policy Change in Ireland

To resolve this untenable situation, the Irish government must take decisive action. The following policy changes are required:

1. Urgent Establishment of a VICP: The government must end the years of delay and act on the “urgent” recommendation made in the 2020 Meenan Report by establishing a statutory, no-fault Vaccine Injury Compensation Programme.
2. Learn from International Models: In designing the scheme, Ireland should draw on the wealth of experience from its European partners. Specifically, it should avoid the UK’s prohibitively high 60% disablement threshold and instead look to the more accessible and comprehensive models seen in Nordic countries, France, and Germany.³⁸
3. Key Design Features for an Irish Scheme:

• Accessible Eligibility Criteria: The threshold for injury severity should be clear, reasonable, and medically informed, allowing for compensation for injuries that are serious and life-altering, even if they do not meet an extreme disablement percentage.
• Fair and Comprehensive Compensation: The scheme should move beyond a simple lump-sum payment. Where appropriate, compensation should be individualised to cover tangible losses, including loss of earnings, medical and care costs, and non-monetary damages for pain and suffering, as is the standard in the most robust European schemes.
• Efficient and Transparent Administration: The claims process must be administrative, non-adversarial, and timely, with a clear right of appeal. The body tasked with administering the scheme must be mandated to publish regular, detailed data on claims received, processing times, and outcomes to ensure public accountability and trust.

Implementing a fair and robust compensation scheme is the only ethical path forward. It would provide meaningful support to the few who have paid a high personal price for a collective benefit, restore faith in the State’s commitment to its citizens, and finally remedy a long-standing failure in Ireland’s legal and social preparedness.

Works cited

1. National Vaccine Injury Compensation Program – HRSA, accessed on June 23, 2025, https://www.hrsa.gov/vaccine-compensation
2. In favour of a bespoke COVID-19 vaccines compensation scheme – PMC – PubMed Central, accessed on June 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7906662/
3. COVID-19 vaccine side effects and safety – HSE.ie, accessed on June 23, 2025, https://www2.hse.ie/screening-and-vaccinations/covid-19-vaccine/side-effects/
4. Vaccine Injury Compensation Programmes: An Overview – Oireachtas, accessed on June 23, 2025, https://data.oireachtas.ie/ie/oireachtas/libraryResearch/2021/2021-04-20_l-rs-note-vaccine-injury-compensation-programmes-an-overview_en.pdf
5. Safety update for reported side effects from Covid-19 Vaccines – Moloney & Co Solicitors, accessed on June 23, 2025, https://moloneysolicitors.ie/safety-update-reported-side-effects-covid-19-vaccines/
6. Vaccine Injury in Ireland – Moloney & Co Solicitors, accessed on June 23, 2025, https://moloneysolicitors.ie/vaccine-injury-page/
7. ‘Disappointment’ as government fails to deliver vaccine compensation scheme, accessed on June 23, 2025, https://www.irishlegal.com/articles/disappointment-as-government-fails-to-deliver-vaccine-compensation-scheme
8. Entitlement to Compensation for Side Effects from COVID-19 Vaccinations, accessed on June 23, 2025, https://mccarthy.ie/blog/medical-negligence-claims/entitlement-to-compensation-for-side-effects-from-covid-19-vaccinations/
9. Government to establish vaccination injury compensation scheme – Irish Claims Service, accessed on June 23, 2025, https://claimsservice.ie/government-to-establish-vaccination-injury-compensation-scheme/
10. vaccine damage steering group – Lenus.ie, accessed on June 23, 2025, https://www.lenus.ie/bitstream/handle/10147/86577/vaccine_report.pdf?sequence=1&isAllowed=y
11. “First Do No Harm”. No-Fault Compensation Program for COVID-19 Vaccines as Feasibility and Wisdom of a Policy Instrument to Mitigate Vaccine Hesitancy – PubMed Central, accessed on June 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8540114/
12. Vaccine injury redress programmes – Health Research Board, accessed on June 23, 2025, https://www.hrb.ie/wp-content/uploads/2024/05/Vaccine_injury_redress_programmes._Final_report-1.pdf
13. COVID-19 Vaccination and Legal Preparedness: Lessons from Ireland in – Brill, accessed on June 23, 2025, https://brill.com/view/journals/ejhl/29/2/article-p240_4.xml
14. Are indemnities for vaccine makers a moral hazard in the making? | Reddy Charlton LLP, accessed on June 23, 2025, https://reddycharlton.ie/insights/are-indemnities-for-vaccine-makers-a-moral-hazard-in-the-making/
15. Vaccine Injury Claims in Dublin: Your Guide to Compensation, accessed on June 23, 2025, https://medicalnegligenceclaim.ie/vaccine-injury-claims-dublin-ireland/
16. Vaccine Damage Payment Scheme (VDPS) – NHSBSA, accessed on June 23, 2025, https://www.nhsbsa.nhs.uk/vaccine-damage-payment-scheme-vdps
17. Vaccine Injury Compensation, Ireland & Covid-19 Claims – McCarthy + Co Solicitors LLP, accessed on June 23, 2025, https://mccarthy.ie/medical-negligence/product-liability/vaccine-injury-compensation/
18. Vaccination Programme – Wednesday, 5 Feb 2025 – Parliamentary …, accessed on June 23, 2025, https://www.oireachtas.ie/en/debates/question/2025-02-05/1105/
19. Vaccination Programme – Tuesday, 26 Jul 2022 – Oireachtas, accessed on June 23, 2025, https://www.oireachtas.ie/en/debates/question/2022-07-26/1941/
20. Vaccination Programme: 5 Feb 2025: Written answers (KildareStreet.com), accessed on June 23, 2025, https://www.kildarestreet.com/wrans/?id=2025-02-05a.3203
21. COVID-19 vaccinations and your indemnity – Medicolegal articles for doctors in Ireland, accessed on June 23, 2025, https://www.medicalprotection.org/ireland/resources-training/articles/covid-19-vaccinations-and-your-indemnity
22. Clinical Risk Insights June 2021 – Editorial – State Claims Agency, accessed on June 23, 2025, https://stateclaims.ie/learning-events/clinical-risk-insights-june-2021-editorial
23. Learning through medication incident reporting – State Claims Agency, accessed on June 23, 2025, https://stateclaims.ie/learning-events/learning-through-medication-incident-reporting
24. Clinical Risk Unit & Snapshot Insights – State Claims Agency, accessed on June 23, 2025, https://stateclaims.ie/uploads/banner/Clinical-Risk-Updates-Lifecycle-of-a-Claim-and-Spotlight-on-Diagnostic-Errors-12-March-2024-Slides.pdf
25. Open Disclosure: the State Claims Agency’s Perspective – HSE, accessed on June 23, 2025, https://www.hse.ie/eng/about/who/nqpsd/qps-incident-management/open-disclosure/webinar-presentation-open-disclosure-the-state-claims-agency-s-perspective-13-april-2022.pdf
26. Vaccination Programme – Wednesday, 21 Feb 2024 – Oireachtas, accessed on June 23, 2025, https://www.oireachtas.ie/en/debates/question/2024-02-21/157/
27. Covid-19 Pandemic Supports – Tuesday, 11 Jun 2024 – Oireachtas, accessed on June 23, 2025, https://www.oireachtas.ie/en/debates/question/2024-06-11/817/
28. Vaccination Programme – Thursday, 29 Feb 2024 – Parliamentary Questions (33rd Dáil) – Houses of the Oireachtas, accessed on June 23, 2025, https://www.oireachtas.ie/en/debates/question/2024-02-29/304/
29. Scheme on the horizon for vaccine damage victims, Limerick TD learns, accessed on June 23, 2025, https://www.limerickpost.ie/2024/05/15/scheme-on-the-horizon-for-vaccine-damage-victims-limerick-td-learns/
30. Vaccine Damage Payment: Eligibility – GOV.UK, accessed on June 23, 2025, https://www.gov.uk/vaccine-damage-payment/eligibility
31. Vaccine Damage Payment | nidirect, accessed on June 23, 2025, https://www.nidirect.gov.uk/articles/vaccine-damage-payment
32. Vaccine Damage Payment: Overview – GOV.UK, accessed on June 23, 2025, https://www.gov.uk/vaccine-damage-payment
33. Vaccine Damage Payment Scheme – media fact sheet, accessed on June 23, 2025, https://healthmedia.blog.gov.uk/2023/05/09/vaccine-damage-payment-scheme-media-fact-sheet/
34. Claim for a Vaccine Damage Payment – NHSBSA, accessed on June 23, 2025, https://www.nhsbsa.nhs.uk/claim-vaccine-damage-payment
35. Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates – PubMed, accessed on June 23, 2025, https://pubmed.ncbi.nlm.nih.gov/40037238/
36. COVID-19 VACCINE DAMAGE PAYMENTS BILL EXPLANATORY NOTES, accessed on June 23, 2025, https://publications.parliament.uk/pa/bills/cbill/59-01/0087/240087en.pdf
37. NFCS KPI Summary – University of Oxford, accessed on June 23, 2025, https://www.law.ox.ac.uk/sites/default/files/2024-07/performance_summary.pdf
38. Covid-19 Vaccine No Fault Compensation Schemes – University of …, accessed on June 23, 2025, https://www.law.ox.ac.uk/sites/default/files/2023-03/Europe%20NFCS%20Report.pdf
39. COVID-19 vaccines – suspected side effects – HPRA, accessed on June 23, 2025, https://www.hpra.ie/safety-information/how-we-monitor-safety/medicines/safety-monitoring-of-vaccines/covid-19-vaccines—suspected-side-effects-reported-in-ireland-and-the-eu-eea
40. Coronavirus vaccine – summary of Yellow Card reporting – GOV.UK, accessed on June 23, 2025, https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
41. Untitled – State Claims Agency, accessed on June 23, 2025, https://stateclaims.ie/uploads/inner/Infographic-Medication-Incidents-2024.pdf
42. Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates – ResearchGate, accessed on June 23, 2025, https://www.researchgate.net/publication/389585323_Comparative_analysis_of_fourteen_COVID-19_vaccine_injury_compensation_systems_and_claim_approval_rates
43. We, Vaccine Injured Bereaved UK (VIBUK), will say as follows, accessed on June 23, 2025, https://covid19.public-inquiry.uk/wp-content/uploads/2025/01/15185619/INQ000474371.pdf
44. Irish Patients Association: Patient Advocacy, accessed on June 23, 2025, https://www.irishpatients.ie/
45. Patient Advocacy Service, accessed on June 23, 2025, https://www.patientadvocacyservice.ie/